A simulation study of approaches for handling disease progression in dose-finding clinical trials. Issue 2 (4th March 2021)

• Record Type: Journal Article
• Authors: Biard, Lucie; Cheng, Bin; Manji, Gulam A.; Lee, Shing M
• Is Part Of: Journal of biopharmaceutical statistics. Volume 31:Issue 2(2021)
• Page Start: 156
• Page End: 167
• Publication Date: 2021-03-04
• Subjects: Dose-finding -- disease progression -- late-onset toxicity -- molecularly-targeted agent -- immunotherapy; Pharmacy -- Statistical methods -- Periodicals; Drugs -- Testing -- Statistical methods -- Periodicals; Biometry -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacokinetics -- Periodicals; 615.19
• DOI: 10.1080/10543406.2020.1814796
• Languages: English
• ISSNs: 1054-3406

Abstract

ABSTRACT: In traditional dose-finding studies, dose-limiting toxicity (DLT) is determined within a fixed time observation window where DLT is often defined as a binary outcome. In the setting of oncology dose-finding trials, often patients in advanced stage of diseases are enrolled. Therefore, disease progression may occur within the DLT observation window leading to treatment discontinuation and rendering the patient unevaluable for DLT assessment. As a result, additional patients have to be enrolled, increasing the sample size. We propose and compare several practical approaches for handling disease progression which occurs within the DLT observation window, while in the framework of the time-to-event continual reassessment method (TITE-CRM) which allows using partial observations. The approaches differ on the way they define an evaluable patient and in the way incomplete observations are included. The practical approaches, which we call strategies A, B and C, are illustrated and contrasted in the context of a single simulated trial, and compared via simulations under various scenarios of dose-progression relationship, in the setting of advanced soft-tissue sarcoma.